Table 3.
Factors that were found to affect the long-term prognosis in IgAN patients in the univariate and multivariate COX regression analyses
| |
Univariate analysis |
|
|
Multivariate analysis |
|
|
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| ALB g/L at month 6 |
0.86 |
0.76-0.96 |
0.01 |
|
|
NS |
| TA-ALB g/L |
0.8 |
0.70-0.93 |
0.002 |
0.86 |
0.75-0.98 |
0.03 |
| Baseline SCr μmol/L |
1.02 |
1.01-1.04 |
0.003 |
|
|
NS |
| SCr μmol/L at month 3 |
1.03 |
1.02-1.05 |
<0.001 |
|
|
NS |
| SCr μmol/L at month 6 |
1.03 |
1.02-1.04 |
<0.001 |
|
|
NS |
| TA-SCr μmol/L |
1.02 |
1.01-1.03 |
<0.001 |
1.02 |
1.01-1.03 |
<0.001 |
| Baseline BUN mmol/L |
1.37 |
1.14-1.65 |
0.001 |
|
|
NS |
| BUN mmol/L at month 3 |
1.35 |
1.15-1.59 |
<0.001 |
|
|
NS |
| BUN mmol/L at month 6 |
1.36 |
1.10-1.69 |
0.005 |
|
|
NS |
| TA-BUN mmol/L |
1.56 |
1.25-1.94 |
<0.001 |
|
|
NS |
| Baseline eGFR (ml/min/1.73 m2) |
0.97 |
0.94-0.99 |
0.01 |
|
|
NS |
| eGFR (ml/min/1.73 m2) at month 3 |
0.96 |
0.94-0.98 |
0.004 |
|
|
NS |
| eGFR (ml/min/1.73 m2) at month 6 |
0.96 |
0.93-0.98 |
0.001 |
|
|
NS |
| TA-eGFR (ml/min/1.73 m2) |
0.96 |
0.93-0.98 |
0.001 |
|
|
NS |
| UPE (g/d) at month 3 |
1 |
1.00-1.002 |
0.003 |
|
|
NS |
| TA-UPE (g/d) | 1 | 1.000-1.002 | 0.01 | NS | ||